Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Now, the person making the call is somebody somewhere who works for (the insurance company). It’s not my physician, who’s an ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves ...

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our ...

Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The positive ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

Side effects of Opdivo vs. Keytruda Both Opdivo and Keytruda treat certain types of cancer. They also belong to the same medication class. Because of this, these drugs can cause some of the same side ...